

FORM PTO-1390  
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

0230-0163P

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/856979

INTERNATIONAL APPLICATION NO.

PCT/JP00/06222

INTERNATIONAL FILING DATE

September 12, 2000

PRIORITY DATE CLAIMED

September 30, 1999

TITLE OF INVENTION

METHOD FOR PRODUCING MALE-STERILE PLANT

APPLICANT(S) FOR DO/EO/US


HAMADA, Kazuyuki and NAKAKIDO, Fumio

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39 (1).
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau. WO 01/24616 A1
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☒ is transmitted herewith.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4)
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 20. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.-1449 and International Search Report w/cited references
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:  
PCT Request PCT/RO/101  
One (1) sheet of formal drawing  
Verification of a translation

U.S. APPLICATION NO (if known, 37 CFR 1.1) <b>09/856979</b>		INTERNATIONAL APPLICATION NO PCT/IP00/06222		ATTORNEY'S DOCKET NUMBER 0230-0163P	
21. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. . . . . <b>\$1,000.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO . . . . . <b>\$860.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO. . . . . <b>\$710.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) . . . . . <b>\$690.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4). . . . . <b>\$100.00</b> <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>CALCULATIONS PTO USE ONLY</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	0
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	11 - 20 =	0	X \$18.00	\$	0
Independent Claims	5 - 3 =	2	X \$80.00	\$	160.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable) Yes			+ \$270.00	\$	270.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$	1,290.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	0
<b>SUBTOTAL =</b>				\$	1,290.00
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	0
<b>TOTAL NATIONAL FEE =</b>				\$	1,290.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +				\$	40.00
<b>TOTAL FEES ENCLOSED =</b>				\$	1,330.00
				Amount to be: refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <b>1,330.00</b> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-2448</u> .  <b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>  Send all correspondence to: <b>Birch, Stewart, Kolasch &amp; Birch, LLP or Customer No. 2292</b> <b>P.O. Box 747</b> <b>Falls Church, VA 22040-0747</b> <b>(703)205-8000</b>  Date: <u>May 30, 2001</u>					
				By  #32,808	
				for Gerald M. Murphy, Jr., #28,977	

/rem

09/856979

531 Rec'd PCT

30 MAY 2001

PATENT  
0230-0163P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: HAMADA, Kazuyuki et al. Conf.:  
Int'l. Appl. No.: PCT/JP00/06222  
Appl. No.: NEW Group:  
Filed: May 30, 2001 Examiner:  
For: METHOD FOR PRODUCING MALE-STERILE  
PLANT

PRELIMINARY AMENDMENT

**BOX PATENT APPLICATION**

Assistant Commissioner for Patents  
Washington, DC 20231

May 30, 2001

Sir:

The following Preliminary Amendments and Remarks are respectfully submitted in connection with the above-identified application.

AMENDMENTS

IN THE SPECIFICATION:

Please amend the specification as follows:

Before line 1, insert --This application is the national phase under 35 U.S.C. § 371 of PCT International Application No. PCT/JP00/06222 which has an International filing date of September 12, 2000, which designated the United States of America and was not published in English.--

**IN THE CLAIMS:**

Please amend the claims as follows:

4. (Amended) A method for producing a male-sterile plant as claimed in claim 1 wherein the first promoter and the second promoters are both promoters causing anther-specific expression.

5. (Amended) A method for producing a male-sterile plant as claimed in claim 1 wherein said first promoter is a part of the promoter represented by SEQ ID No:6.

6. (Amended) A method for producing a male-sterile plant as claimed in claim 1 wherein said first promoter is the promoter represented by SEQ ID NO:7.


REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application. The claims have also been amended to delete improper multiple dependencies and to place the application into better form for examination.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #32868  
for Gerald M. Murphy, Jr., #28,977

GMM/rem  
0230-0163P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

(Rev. 02/12/01)

09/856979

Docket No.0230-0163P Error! Reference source not found.

531 Rec'd PCT  
VERSION WITH MARKINGS TO SHOW CHANGES MADE

30 MAY 2001


IN THE CLAIMS:

The claims have been amended as follows:

4. (Amended) A method for producing a male-sterile plant as[claimed in claim 1 to 3] claimed in claim 1 wherein the first promoter and the second promoters are both promoters causing anther-specific expression.

5. (Amended) A method for producing a male-sterile plant as [claimed in any of claims 1 to 4] claimed in claim 1 wherein said first promoter is a part of the promoter represented by SEQ ID No:6.

6. (Amended) A method for producing a male-sterile plant as[claimed in any of claims 1 to 5] claimed in claim 1 wherein said first promoter is the promoter represented by SEQ ID NO:7.



533 Rec'd PCT/PTO 04 SEP 2001

RET #6  
Box 1807PATENT  
0230-0163P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: K. HAMADA et al. Conf.: 6058  
Appl. No.: 09/856,979 Group: UNASSIGNED  
Filed: May 30, 2001 Examiner: UNASSIGNED  
For: METHOD FOR PRODUCING MALE-STERILE PLANT

LARGE ENTITY TRANSMITTAL FORM

Assistant Commissioner for Patents  
Washington, DC 20231

September 4, 2001

Sir:

Transmitted herewith is an amendment in the above-identified application.

- ☐ The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.
- ☐ The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	11	-	20	=	0	\$18	\$0.00
INDEPENDENT	5	-	5	=	0	\$80	\$0.00
<input type="checkbox"/> FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM						\$270	\$0.00
						TOTAL	\$0.00

- ☐ Petition for ( ) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$0.00 for the extension of time.
- ☒ No fee is required.
- ☐ A check in the amount of \$0.00 is enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Gerald M. Murphy, Jr. (Reg. No. 40,069)  
Gerald M. Murphy, Jr., #28,977

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

GMM/CAV  
0230-0163P

ATTACHMENT





10 RSC 111

04 SEP 2001

#6

BOX SEQUENCE

PATENT

0230-0163P

## IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: K. HAMADA et al. Conf.: 6058  
Appl. No.: 09/856,979 Group: UNASSIGNED  
Filed: May 30, 2001 Examiner: UNASSIGNED  
For: METHOD FOR PRODUCING MALE-STERILE PLANT

AMENDMENT

Assistant Commissioner for Patents  
Washington, DC 20231

September 4, 2001

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed July 3, 2001, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

In the Specification:

Please delete pages 1-11 of the Sequence Listing originally filed on May 30, 2001 located immediately after the Abstract. Please insert the Substitute Sequence Listing enclosed herewith immediately after the abstract.

REMARKS

Enclosed herewith in full compliance to 37 C.F.R. §§1.821-1.825 is a Substitute Sequence Listing to be inserted into the Specification as indicated above. The Substitute Sequence Listing in no way introduces new matter into the Specification. Also submitted herewith in full compliance to 37 C.F.R. §§1.821-1.825 is a disk copy of the Substitute Sequence Listing. The disk copy of the Sequence Listing, file "0230-0163P.ST25", is identical to the paper copy, except that it lacks formatting.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By Margaret Murphy (By No 46068)  
Gerald M. Murphy Jr., #28,977

GMM/CAV  
0230-0163P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachments:      Disk Copy of Sequence Listing  
                     Paper Copy of Sequence Listing  
                     Copy of Notice to Comply

(Rev. 03/27/01)

VERIFICATION OF A TRANSLATION

I, the below named translator, hereby declare that:

My name and post office address are as stated below;

That I am knowledgeable in the English language and in the language in which the below identified application was filed, and that I believe the English translation of International Application No. PCT/JP00/06222 is a true and complete translation of the above identified International Application as filed.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Dated this 29th day of May, 2001

Full name of the translator: Kiyoshi MURAKAMI

Signature of the translator: Kiyoshi Murakami

Post Office Address: c/o YUASA AND HARA, Section 206,  
New Ohtemachi Bldg., 2-1,  
Ohtemachi 2-chome, Chiyoda-ku,  
Tokyo, JAPAN

1/PRTS

09/856979

531 Rec'd P

20 MAY 2001

# SPECIFICATION

## METHOD FOR PRODUCING MALE-STERILE PLANT

The present application claims priority from Japanese Patent Application Hei 11-279307 filed on September 30, 1999, the disclosure of which is incorporated herein by reference.

## FIELD OF THE INVENTION

This invention relates to a method for producing a male-sterile plant by gene manipulation.

## 10 PRIOR ART

Barnase is an RNase derived from *Bacillus amyloliquefaciens* (S. Nishimura and M. Nomura, Biochem. Biophys. Acta 30, 430-431:1958; R.W. Hartley, J. Mol. Biol., 202, 913-915:1988). It is an enzyme having 110 amino acid residues and hydrolyzing RNA. When expressed in cells, this enzyme inhibits the functions of the cells owing to its potent RNase activity and thus causes cell death in many cases. By using this characteristic, it is therefore expected that expressing the barnase gene in a specific site of a plant would result in the selective regulation of the function of that site.

PCT WO89/10396 discloses a technique whereby a male-sterile plant is obtained by constructing a male sterility gene by ligating the above-described barnase gene to the downstream of an anther tapetal cell-specific expression promoter and transferring the thus obtained gene into a plant. This male sterilization technique is highly useful in efficiently developing an F1 hybrid variety.

When a barnase gene is employed as a male sterility gene, however, it is frequently observed that the thus obtained male- sterile transgenic plant exhibits unfavorable characteristics. PCT WO96/26283 refers to this problem in rice. It is also reported that similar phenomena are observed in lettuce (Scientia Horticulturae 55, 125-139:1993; Arlette Reymaerts, Hilde Van de Wiele, Greta De Sutter, Jan Janssens: Engineered genes for fertility control and their application in hybrid seed production). According to this report, a plant with depressed activity was constructed by transferring a male sterility gene comprising a tobacco-origin anther-specific promoter (TA29) and barnase into lettuce.

Although the causes of these phenomena have not been accurately determined so far, it is assumed that the so-called "position effect" of the gene transfer site might affect the mechanism (PCT WO96/26283). More specifically, the aimed male-sterile plant can be constructed when the male sterility gene is expressed exclusively in the target site (i.e., anthers). However, there is a possibility that the barnase might be expressed, even though in an extremely small amount, in tissues other than anthers under the action of an expression regulator (for example, an endogenous enhancer) existing in the vicinity of the gene transfer site. In such a case, the unfavorable characteristics as described above might arise due to the potent enzymatic activity.

To overcome this problem, PCT WO96/26283 discloses a

method using cauliflower mosaic virus 35S promoter  
(hereinafter referred to as CaMV35S promoter) which is  
expressed potently in tissues other than anthers. Namely,  
a Barstar, i.e., an inhibitory protein against barnase is  
5 employed therein. The Barstar gene ligated to the CaMV35S  
promoter is transferred into a plant simultaneously and  
then the Barstar gene is constitutively expressed in  
tissues other than anthers, thereby eliminating the effects  
of the barnase on tissues other than anthers.

10 In the male-sterile plant constructed by this method,  
however, the Barstar gene is expressed in the whole plant  
including leaves and albumen that is an edible part. It is  
not desirable from the viewpoint of the public acceptance  
of transgenic crops that the Barstar protein is expressed  
15 in parts where its expression is unnecessary.

#### SUMMARY OF THE INVENTION

The present invention provides a method for producing  
a male-sterile plant that has normal morphology comparable  
to the intact species but being male-sterile.

20 The present invention provides a method for producing  
a male-sterile plant by expressing a foreign RNase in the  
anthers of the plant wherein the expression of the foreign  
RNase in tissues other than anthers is inhibited as much as  
possible to thereby construct a male-sterile plant showing  
25 normal morphology comparable to the original (i.e., intact)  
plant.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a model view which shows the structure of

plasmid pTS346 for transforming plant cells which contains a Barstar gene under the control of an anther-specific E1 promoter and a barnase gene under the control of an anther-specific E1 promoter fragment in order from the 5'-end to the 3'-end.

#### DETAILED DESCRIPTION OF THE INVENTION

The present inventors obtained two male sterile lines showing improvement in that they respectively exhibited a smaller degree of morphological abnormality from among rice male-sterile lines having been transfected with a genetic construct prepared by ligating a barnase gene to an anther-specific E1 promoter originating in rice. By analyzing these lines, it was found that the E1 promoter had been divided into two parts by an about 10 kb transposon originating in *Agrobacterium tumefaciens* LBA4404 employed in the transformation of rice. Based on this fact, it was assumed that the effect of the upper part of the E1 promoter on the expression of the barnase gene would have been compromised by the intervention of the transposon of 10 kb or more and, as a result, the expression of the barnase gene would have been depressed giving rise to the alleviation of morphological abnormality.

This finding indicated that the problem of the expression of an RNase in tissues other than anthers encountered in the conventional art would be overcome if an RNase gene (for example, a barnase gene) is ligated to the downstream of an anther-specific promoter which is made shorter than the full length (i.e., a promoter fragment)

and the resultant construct is transferred into a plant genome. From this viewpoint, the present inventors further conducted intensive studies and thus produced a transgenic rice plant by transferring a Barstar gene ligated to the downstream of a rice anther-specific E1 promoter simultaneously with an RNase gene ligated to a fragment of an anther-specific promoter fragment, thereby achieved further improvement in the morphology of male-sterile rice lines.

Accordingly, the present invention provides a method for producing a male-sterile plant characterized by comprising ligating a first promoter fragment to the upstream of an RNase gene, further ligating a second promoter, which is the same as the first promoter or different therefrom, to the upstream of an RNase inhibitor protein gene, and transferring these genes into a plant genome to thereby make the plant substantially male-sterile.

It is preferable that the RNase gene to be used in the present invention is barnase gene. Barnase gene may be employed as such. Alternatively, it may be naturally or artificially mutated so as to modify the activity of the enzyme encoded thereby or the tissue specificity thereof. For the purpose of the present invention, use can be made of the gene of any enzyme which can act as an RNase in plant cells (in particular, anthers) and thus inhibit protein biosynthesis in the cells. Examples of such enzymes include pancreas RNase A, RNase T1 from *Aspergillus oryzae* and Sarnase originating in *Streptomyces aureofaciens*



(European Patent Publication No. 053799).

The promoter to be ligated to the upstream of the RNase gene (i.e., the first promoter) can be any promoter, which can induce the expression of the RNase gene to be employed in plant cells. As examples, tobacco TA29 promoter (J. Seurinck et al., Nuc. Acid. Res., 18, 3403, 1990) and *Arabidopsis* A9 promoter (Wyatt Paul et al., Plant Mol. Biol., 19, 611-622, 1992) may be mentioned. It is preferable that the first promoter is a promoter specific to the anther of the plant which is to be made male-sterile. In the case of rice, there are known anther-specific promoters such as E1 promoter, T72 promoter, T42 promoter (each described in PCT WO92/13956), Osg6B promoter, Osg4B promoter (each reported by T. Tsuchiya et al., Plant Mol. Biol. 26, 1737-1746, 1994) and the like. The sequence of the E1 promoter is represented by SEQ ID NO:6.

It is essential to use the first promoter as a fragment. The term "fragment" as used herein in connection with the first promoter means a sequence that at least partly differs from the promoter sequence occurring in nature. For example, the fragment is a promoter having deletion, substitution or insertion in the 3'-region, the internal region and/or the 5'-region including a case of being divided into upstream and downstream regions with an intervening sequence. It is preferable that, as a result of the deletion, substitution or insertion, the fragment has up to about 50% homology, still preferably up to about 70% homology and particularly preferably up to about 90%

homology, with the natural promoter sequence. As one of the preferable examples of the first promoter fragments, the fragment originating in the E1 promoter as represented by SEQ ID NO:7 may be mentioned. Also, it is preferable to use, as the first promoter fragment, a sequence obtained by modifying the above-described sequence by substitution, deletion or insertion of one or more nucleotides, so long as it has the same promoter activity as the fragment represented by SEQ ID NO:7. The expression "to modify by substitution, deletion or insertion of nucleotides" as used herein means such a modification as is available by subjecting, for example, ten or less (preferably five or less) nucleotides to artificial manipulation such as site-specific mutagenesis.

The first promoter fragment is ligated to the upstream of the RNase gene in a functional manner. The term "functional" means that the promoter fragment is ligated to such a position as allowing inducing the expression of the RNase gene.

It is also essential in the present invention to use an RNase inhibitor protein gene. This gene may be appropriately selected depending on the RNase gene employed. In the case where the RNase gene is barnase gene, for example, it is preferable to use Barstar gene as the RNase inhibitor protein gene. A second promoter is ligated in a functional manner to the upstream of the RNase inhibitor protein gene. The second promoter, which induces the expression of the RNase inhibitor protein gene to be

employed in plant cells, may be either the same as the first promoter or different therefrom. In case where the second promoter is the same as the first promoter, it is not always necessary to employ the second promoter in the form of a fragment.

The RNase gene, which has been ligated to the first promoter fragment in a functional manner, may be located either downstream or upstream of the RNase inhibitor protein gene which has been ligated to the second promoter in a functional manner. Also, the distance between these genes is not particularly limited.

The plant that can be made male-sterile by the method of the present invention is not particularly limited. As examples thereof, rice, corn, tobacco, lettuce and rapeseed may be mentioned. Among all, rice and corn are particularly preferable.

To transfer the genes into a plant genome to make the plant male-sterile in the method of the present invention, use may be made of the Agrobacterium method, the electroporation method, the particle gun method, etc. It is preferable to use the Agrobacterium method. Details of the procedure may be appropriately determined by a person skilled in the art by reference to, for example, the method described in PCT WO92/13957. For example, the genes can be transferred into a plant cell genome by the following steps:

- (1) providing a first promoter fragment;
- (2) providing an RNase gene;

(3) ligating the RNase gene to the downstream of the first promoter fragment in a functional manner;

(4) providing a second promoter;

(5) providing an RNase inhibitor protein gene;

5 (6) ligating the RNase inhibitor protein gene to the downstream of the second promoter in a functional manner;

(7) integrating the RNase gene, which has been ligated to the downstream of the first promoter fragment, and the RNase inhibitor protein gene, which has been  
10 ligated to the downstream of the second promoter, into T-DNA with the use of restriction enzyme sites;

(8) inserting the T-DNA from step (7) into a Ti plasmid;

(9) amplifying the Ti plasmid from step (8) in an  
15 agrobacterium host cells, if needed; and

(10) infecting plant cells with the agrobacterium from step (9) in order to transfer the RNase gene, which has been ligated to the downstream of the first promoter fragment, and the RNase inhibitor protein gene, which has  
20 been ligated to the downstream of the second promoter, into the genome of the plant cells.

The transgenic plant cells thus obtained can be regenerated into an individual plant starting with callus culture by using the method described in, for example, Y.  
25 Hiei et al., Plant J. 6, 271-282:1994.

In the above-described process, the first promoter fragment may be prepared by cleaving the first promoter with appropriate restriction enzymes. Alternatively, it

may be prepared by amplifying the sequence, which is obtained by deleting unnecessary regions from a plasmid containing the first promoter and the RNase gene, by PCR with the use of appropriate primers, as will be described in Example hereinafter. Also, it is to be understood that various changes in the order of the above steps (in particular, steps (1) to (7)) or materials employed therein fall within the scope of the present invention. Further, it is possible to transform plant cells by using Ti plasmids containing different T-DNAs, of which one carrying the RNase gene which has been ligated to the downstream of the first promoter fragment, while the other carrying the RNase inhibitor protein gene which has been ligated to the downstream of the second promoter. Furthermore, calluses having the transferred genes can be easily selected by preliminarily providing a selection marker in the T-DNA of the step (7). Examples of such a marker include Bar gene employed in the following Example and a hygromycin resistant (HPT) gene. However, it is not always necessary to use a selection marker. The achievement of transformation may be judged based on the fact that the plants regenerated from calluses of transgenic cells have been made male-sterile.

The present invention further provides a vector for transferring the above genes into a plant cell genome by the agrobacterium method as described above. This is a vector which has a T-DNA containing i) a promoter fragment and an RNase gene expressible under the control of said

promoter, and ii) a promoter being the same as the above-described promoter or different therefrom and an RNase inhibitor protein gene expressible under the control of said second promoter, so that the vector can transfer the

5 T-DNA into a plant cell genome when placed in an agrobacterium-infected plant cells. It is preferable that the vector of the present invention is constructed by integrating the T-DNA containing the above-described genetic elements i) and ii) into Ti plasmid for

10 transforming plants. Various Ti plasmids for transforming plants are known and available at present. For example, pAL4404 carried by *Agrobacterium tumefaciens* strain LBA4404 can be mentioned. The vector according to the invention may contain, if necessary, one or more elements selected

15 from among a replication origin for amplification in an agrobacterium, terminators located respectively downstream of the RNase gene and the RNase inhibitor protein gene and/or a marker gene appropriate for selecting transgenic plant cells.

20 The present invention furthermore provides a transgenic plant cell which contains i) a promoter fragment and an RNase gene expressible under the control of said promoter, and ii) a promoter being the same as the above-described promoter or different therefrom and an RNase

25 inhibitor protein gene expressible under the control of said promoter, having been transferred into the genome, and a male-sterile plant regenerated from said transgenic cell.

EFFECT OF THE INVENTION

A male-sterile plant, which exhibits less or no abnormalities in morphology or flowering properties compared with male-sterile plants made by the conventional constructs, can be produced by transferring a barnase gene  
5 ligated under a promoter having a reduced activity due to the deletion of an upstream region together with a Barstar gene ligated under a rice anther-specific promoter, and introducing these genes into the genome of a plant cell.

Now, the present invention will be illustrated in  
10 greater detail with reference to the following Example. However, it is to be understood that the invention is not to be construed as being restricted thereto.

#### Example

As a template for amplifying a barnase gene ligated  
15 to the downstream of an E1 promoter fragment, use was made of plasmid pTS172 (Japanese Patent Application Hei 10-220060). After amplifying by the PCR method with the use of primers 172del-F (SEQ ID NO:1) and 172del-R (SEQ ID NO:2) each having a PstI cleavage site, the obtained  
20 product was treated with PstI. Thus, a fragment of E1 promoter from pTS172 was obtained. The fragment had a cohesive end at each side and comprised exclusively of about a 360 bp sequence including the initiation point and its upstream of the E1 promoter. The both ends of this  
25 fragment were ligated together to cyclize it again by using T4 DNA ligase in a conventional manner, thus giving a novel plasmid pTS172Δ (SEQ ID NO:3). That is to say, in the plasmid pTS172Δ, the E1 promoter region (about 1.7 kb) of

the original plasmid pTS172 was substituted by the 356 bp fragment represented by SEQ ID NO:7.

Next, a fragment (SEQ ID NO:4) comprising an E1 promoter (PCT WO92/13956) ligated to a Barstar gene (R.W. Hartley, J. Mol. Biol. 202, 913-915:1988) was blunt-ended and integrated into the PstI site of pTS172 $\Delta$  to give a plasmid pTS346 (SEQ ID NO:5). Fig. 1 illustrates the structure of pTS346.

A 5.5kb fragment was excised from pTS346 with EcoRI and then inserted into the EcoRI site of pSB11BS (the structure of which will be described just below). Further, the T-DNA region was integrated into an acceptor vector pSB1 (T. Komari et al., Plant J. 10, 165-174:1996) by way of homologous recombination. The resulted recombinant plasmid (pSB1346) was introduced into *Agrobacterium tumefaciens* LBA4404, which was used in transforming rice (variety: Asanohikari). The plasmid pSB11BS was constructed by integrating the Barstar gene (R.W. Hartley, J. Mol. Biol. 202, 913-915:1988) into the StuI site of intermediate vector pSB11 (T. Komari, Plant J. 10, 165-174:1996).

By this *Agrobacterium tumefaciens* LBA4404 having the recombinant plasmid, rice (variety: Asanohikari) was transformed. Although the transformation was performed basically in accordance with the method of Hiei et al. (Plant J. 6, 271-282:1994), phosphinothricin (concentration: 10 mg/L) was employed for screening transgenic plants since the male sterility-gene construct



contained a bar gene encoding phosphinothricin acetyl transferase as a selection marker.

A comparison with the construct pSB1172 (refer to PCT/JP99/04167 filed on August 3, 1999) comprising an E1  
5 promoter of the normal length but lacking any Barstar gene indicated that the transformation efficiency and the ratio of transgenic plants with normal morphology were remarkably improved as shown in the following table.

10 Table 1: Transformation efficiency

	No. of infected calluses	No. of re-differentiated calluses	No. of PCR-positive lines	No. of morphologically normal male sterile lines
pSB1346	681	45	37/38*	15/37 (40.5%)
pSB1172 (control)	2838	83	52/83	9/52(17.3%)

\*: examined 38 lines among 45.

## SEQUENCE LISTING

<110> Japan Tobacco Inc.

<120> Method for producing male-sterile plant

<130> 991862

<160> 7

<210> 1

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer 172del-F

<400> 1

ggctgcagtg cggccgctag cctaggcccg ggcccacaaa aatctg

46

<210> 2

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer 172del-R

<400> 2

gggctgcagt cagccagcca gaccaatggg ggcaaaattt ac

42

<210> 3

<211> 5228

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid pTS172Δ

<400> 3

aattcaagct tgacgtcagg tggcactttt cggggaaatg tgcgcggaac ccctatttgt 60  
ttatttttct aaatacattc aaatatgtat ccgtcatga gacaataacc ctgataaatg 120  
cttcaataat attgaaaaag gaagagtatg agtattcaac atttccgigt cgcccttatt 180  
cccttttttg cggcattttg ccttctgttt ttigtctacc cagaaacgct ggtgaaagta 240  
aaagatgctg aagatcagtt ggggtgcacga gtgggttaca tcgaactgga tctcaacagc 300  
ggtaagatcc ttgagagttt tcgccccgaa gaacgttttc caatgatgag cactttttaa 360  
gttctgctat gtggcgcggt attatcccgt attgacgccg ggcaagagca actcggctgc 420  
cgcatacact attctcagaa tgacttgggt gagtactcac cagtcacaga aaagcatctt 480  
acggatggca tgacagtaag agaattatgc agtgcgtcca taacatgag tgataacact 540  
gcggccaact tacttctgac aacgatcggg ggaccgaagg agctaaccgc ttttttgac 600  
aacatggggg atcatgtaac tcgccttgat cgttgggaac cggagctgaa tgaagccata 660  
ccaaacgacg agcgtgacac cacgatgcct gtagcaatgg caacaacgtt gcgcaaaacta 720  
ttaactggcg aactacttac tctagcttcc cggcaacaat taatagactg gatggaggcg 780  
gataaagttg caggaccact tctgcgctcg gcccttccgg ctggctgggt tattgctgat 840  
aaatctggag ccggtgagcg tgggtctcgc ggtatcattg cagcactggg gccagatggt 900  
aagccctccc gtatcgtagt tatctacacg acggggagtc aggcaactat ggatgaacga 960  
aatagacaga tcgctgagat aggtgccctc ctgattaaagc attggttaact gtcagaccaa 1020  
gittactcat atatacttta gattgattta aaacttcatt ttttaatttaa aaggatctag 1080  
gigaagatcc tttttggctc gagtctcatg accaaaatcc cttaacgtga gttttcgttc 1140  
cactgagcgt cagaccccggt agaaaagatc aaaggatctt cttgagatcc tttttttctg 1200  
cgcgtaatct gctgcttgca aacaaaaaaa ccaccgtac cagcgggtgggt ttgtttgccg 1260  
gatcaagagc taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca 1320  
aatactgtcc ttctagtgtg gccgtagtta ggccaccact tcaagaactc tgtagcaccg 1380  
cctacatacc tcgctctgct aatccgttta ccagtggctg ctgccagtgg cgataagtcg 1440  
tgtcttaccg ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga 1500  
acgggggggt cgtgcacaca gcccagcttg gagcgaacga cctacaccga actgagatac 1560  
ctacagcgtg agcattgaga aagcgccacg ctccccgaag ggagaaaggc ggacaggtat 1620  
ccggttaagcg gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc 1680





tcctagtctg cgcgctatat ttgttttct atcgcgtatt aaatglataa ttgcgggact 120  
 ctaatcataa aaacccaatct caataataac gtcattgatt acatgttaat tattacatgc 180  
 ttaacgtaat tcaacagaaa ttatatgata atcatcgcaa gaccggcaac aggattcaat 240  
 cttagaagaaac ttatttgcca aatgtttgaa cgatctgcct cggagggtac cttagaagaaag 300  
 tatgatgggtg atgtcgcagc ctcccgcttt cgcttcacgg aaaacctgaa gcacactctc 360  
 ggcgccattt tcagtcagct gcttgctttg ttcaaaactgc ctccattcca aaacgagcgg 420  
 gtactccacc catccggta gacaatccca taaagcgctc aggttttcac cgtagtattc 480  
 cggaagggca agctcccttt tcaatgtctg gtggagggtcg ctgatacttc tgatttgctc 540  
 cccgttaatg actgcttttt tcatcgcgac ggcttgatgg atctcttgct ggacaccggg 600  
 atgctaggat gggttatcgt ggccggcgctg cgtgtgtggc ttgtgtaggc gccggcgacg 660  
 gcgggggcaa tgtggcaggt gattcacggg gcaagcgtgc gcaagtact gcaacaacca 720  
 aggacggta tggcgaaagc acctcacgag tccaccgtct acaggatgta gcagtagcac 780  
 ggtgaaagaa gttgtgtccc gtccattagg tgcattctca ccgttggcca gaacaggacc 840  
 gttcaacagt taggttgagt gtaggacttt tacgtggta atgtatggca aatagtagta 900  
 aattttgccc ccattggctt ggctgagata gaacatattc tggaaagcct ctagcatatc 960  
 ttttttgaca gctaaacttt gcttcttgcc ttcttggtct agcaatgacg ttgcccattg 1020  
 cgtggcaaac atctggtaag gtaactgtat tctgtgttc cttcaacgg ctcaatcccc 1080  
 acaggccaag ctatcccttc ctgggcagta taggcctctt gagagattat actaccattt 1140  
 ttaagtgttt ataaagacga tgcctcttaa ccagatcgat cagaaacaca aagttttagc 1200  
 agcgtaatat cccacacaca tacacacacg aagctatgcc tcctcatttt ccgagagatt 1260  
 ctgacagtga ccagaatgtc agaattgcat ttcatgggca caagtcgac cacaagcttc 1320  
 ttgggtggagg tcaaggtgtg ctattattat tgcctttcta ggaaattatt cagaattagt 1380  
 gccttttatt ataacttctc tctgagccga tgtgtgtttg gatttcattg ttgggagcta 1440  
 tgcagttgcg gatattctgc tgtggaagaa caggaactta tctgcggggg tccttgcttg 1500  
 ggcaacattg atattgttcc tgttcgatgt agtagaatac aatataattc cgctcccttg 1560  
 ccagattgcc attcttgcca tgccttgat ctcatattgg tcaaatgccg caccactctt 1620  
 ggacaggta tagctttatt tctgtggag atggtagaaa actcagctta cagaaatggc 1680  
 atttcacgta gtataacgca agacattagg tactaaaact caactaactg ttccgaatt 1740  
 tcaggggccc tccaaggatc ccagaaatca tcatctctga acatgccttc agagaaatgg 1800  
 cattgaccgt ccattacaaa ctaacgtaca ctgtaatgt tctttacgac attgcatgtg 1860  
 gaaaggatct gaagagattt ctcttggtac ataataatct actcctttgc tacgttaata 1920  
 agagatgtaa aaacatgcaa cagttccagt gccaacattg tccaaggatt gtgcaattct 1980  
 ttctggagcg ctaaaattga ccagattaga cgcattcagaa tattgaattg cagagttagc 2040  
 caataatcct cataatgtta atgtgctatt gttgttact actcaatata gttctggact 2100  
 aacaatcaga ttgtttatga tattaagggt gttggatctc tattggtatt gtcggcgatt 2160  
 ggaagtictt gcagcttgac aagcttacta tatattggta ggtattccag ataaatatta 2220

aatitttaata aaacaatcac acagaaggat ctgcggccgc tagcctagge ccggg 2275

<210> 5

<211> 7492

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid pTS346

<400> 5

aattcaagct tgacgtcagg tggcacitit cggggaaatg tgcgcggaac ccctatttgt 60  
ttatititct aaatacattc aaataatgat ccgtcatga gacaataacc ctgataaatg 120  
cttcaataat attgaaaaag gaagagtatg agtattcaac atttccgigt cgcccttatt 180  
ccctitititg cggcatititg ccttctctgt tttgtctacc cagaaacgct ggtgaaagta 240  
aaagatgctg aagatcagtt ggggtgcacga gtgggttaca tcgaactgga tctcaacagc 300  
ggtaagatcc ttgagagtitt tgcctccgaa gaacgtititc caatgatgag cactititaaa 360  
gttctgtctat gtggcgcggt attatccctg attgacgccg ggcaagagca actcggctgc 420  
cgcatacact attctcagaa tgacttgggt gagtactcac cagtcacaga aaagcatctt 480  
acggatggca tgacagliaag agaattatgc agtctgcca taacctgag tgataacact 540  
gcggccaaact tacttctgac aacgatcgga ggaccgaagg agctaaccgc ttttttgac 600  
aacatggggg atcatgtaac tgccttggat cgttgggaac cggagctgaa tgaagccata 660  
ccaaacgacg agcgtgacac cacgatgcct gtagcaatgg caacaacgtt gcgcaacta 720  
ttaactggcg aactacttac tctagcttcc cggcaacaat taatagactg gatggaggcg 780  
gataaagttg caggaccact tctgcgctcg gcccttccgg ctggctgggt tattgtctgat 840  
aaatctggag ccggtgagcg tgggtctcgc ggtatcattg cagcactggg gccagatggt 900  
aagccctccc gtatcgtagt tatctacacg acggggagtc aggcaactat ggatgaacga 960  
aatagacaga tgcctgagat aggtgcctca ctgattaaagc attggtaact gtcagaccaa 1020  
gtttactcat atatacttta gattgattta aaacttcatt ttttaatttaa aaggatctag 1080  
gtgaagatcc ttttggctc gagtctcatg accaaaatcc cttaacgtga gtttctgtc 1140  
cactgagcgt cagacccctg agaaaagatc aaaggatctt cttgagatcc ttttttctg 1200  
cgcgtaatct gctgcttgca aacaaaaaaa ccaccgctac cagcgggtgt ttttttgcg 1260  
gatcaagagc taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca 1320  
aatactgtcc ttctagtgtg gccgtagtta ggccaccact tcaagaactc tgtagcaccg 1380  
cctacatacc tctgtctgtc aatcctgtta ccagtggctg ctgccagtgg cgataagtcg 1440

tgtcttaccg ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga 1500  
 acgggggggtt cgtgcacaca gcccagcttg gagcgaacga cctacaccga actgagatac 1560  
 ctacagcgtg agcattgaga aagcgccacg ctccccgaag ggagaaaggc ggacaggta 1620  
 ccggtaaagc gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc 1680  
 tggatcttt atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga 1740  
 tgctcgtcag gggggcggag cctatggaaa aacgccagca acgcggcctt ttacgggtc 1800  
 ctggcctttt gctggccttt tgctcacatg ttctttcctg cgttatcccc tgattctgtg 1860  
 gataaccgta ttaccgcctt tgagttagct gataccgctc gccgcagccg aacgaccgag 1920  
 cgcagcgagt cagttagcga ggaagcgga gagcgcccaa tacgcaaacc gcctctcccc 1980  
 gcgcgttggc ctgatcagaa ttcatatgca cgtgttcccc atctagtaac atagatgaca 2040  
 ccgcgcgcga taatttatcc tagtttgcgc gctatatttt gttttctatc gcgtattaaa 2100  
 tgtataattg cgggactcta atcataaaaa ccatctcat aaataacgtc atgcattaca 2160  
 tgttaattat tacaigctta acgtaattca acagaaatta tatgataatc atcgcaagac 2220  
 cggcaacagg attcaatctt aagaaacttt attgccaaat gtttgaacga tctgcttcgg 2280  
 aggttacctt atctgatttt tgtaaaggct tgataatggt cgttgttttt gtaaatacagc 2340  
 cagtcgcttg agtaaagaat ccggtctgaa ttcttgaagc ctgatgtata gtttaatacc 2400  
 gcttcacgcc atgttcgtcc gcttttggcc gggagtttgc ctccctgtt tgagaagatg 2460  
 tctccgccga tgcctttccc cggagcgacg tctgcaaggt tcccttttga tgccaccag 2520  
 ccgagggctt gtgcttctga ttttgtaatg taattatcag gtagcttatg atatgtctga 2580  
 agataatccg caaccccgct aaacgtgttg ataaccggtt ccatcgcgac ggcttgatgg 2640  
 atctcttgct ggacaccggg atgctaggat gggttatcgt ggccggcgctg cgtgtgtggc 2700  
 ttttgtaggc gccggcgacg gcgggggcaa tgtggcaggt gagtacaggt gcaagcgtgc 2760  
 gcaagtgact gcaacaacca aggacggtca tggcgaaagc acctcacgcg tccaccgtct 2820  
 acaggatgta gcagtagcac ggtgaaagaa gtgttgtccc gtccattagg tgcattctca 2880  
 ccgttggcca gaacaggacc gtccaacagt taggttagat gtaggacttt tacgtggta 2940  
 atgtatggca aatagtagta aattttgccc ccattggtct ggctgacaat tcatatgcac 3000  
 gtgttcccga tctagtaaca tagatgacac cgcgcgcgat aatttatect agtttgcgcg 3060  
 ctatattttg ttttctatcg cgtattaaat gtataattgc gggactctaa tcataaaaac 3120  
 ccatctcata aataacgtca tgcattacat gttaattatt acatgcttaa cgtaattcaa 3180  
 cagaaattat atgataatca tcgcaagacc ggcaacagga ttcaatctta agaaacttta 3240  
 ttgccaaatg ttgaaacgat ctgcttcgga ggttacctta agaaagtatg atggatgat 3300  
 cgcagccttc cgttttcgt tcacggaaaa cctgaagcac actctcggcg ccattttcag 3360  
 tcagctgctt gctttgttca aactgcctcc attccaaaac gagcgggtac tccaccatc 3420  
 cggtcagaca atccataaaa gcgtccaggt ttaccaggta gtattccgga agggcaagct 3480  
 cctttttcaa tgtctggtgg aggtcgttga tacttctgat ttgttccccg ttaatgactg 3540  
 cttttttcat cgcgacggct tgaatgatat ctgtctggac accgggatgc taggatgggt 3600





aatgagaagg ttagcctctt caatttcaga aagaatgctg acccacagat ggtagagag 5820  
gcctacgcag caggctctcat caagacgacg taccgcagta acaatctcca ggagatcaaa 5880  
taccttccca agaaggttaa agatgcagtc aaaagattca ggactaattg catcaagaac 5940  
acagagaaaag acatatttct caagatcaga agtactattc cagtatggac gattcaaggc 6000  
ttgcttcata aaccaaggca agtaatagag attggagctt ctaaaaaggt agttcctact 6060  
gaatctaagg ccatgcatgg agtctaagat tcaaatcgag gatctaacag aactcgccgt 6120  
gaagaciggc gaacagttca tacagagctt ttacgactc aatgacaaga agaaaatctt 6180  
cgtcaacatg gtggagcagc acactctggt ctactccaaa aatgtcaaag atacagtctc 6240  
agaagaccaa agggctattg agacttttca acaaaggata atttcgggaa acctcctcgg 6300  
attccattgc ccagctatct gtcacttcat cgaaaggaca gtagaaaagg aagggtggctc 6360  
ctacaaatgc catcattgcg ataaaggaaa ggctatcatt caagatgcct ctgccgacag 6420  
tggtcccaaa gatggacccc caccacgag gagcatcgtg gaaaaagaag acgttccaac 6480  
cacgtcttca aagcaagtgg attgatgtga catctccact gacgtaaggg atgacgcaca 6540  
atcccactat ccttcgcaag acccttctc tatataagga agttcatttc atttggagag 6600  
gacacgctga aatcaccagt ctctctctat aaatctatct ctctctctat aacctggac 6660  
ccagaacgac gcccgccga catccgccgt gccaccgagg cggacatgcc ggcggctcgc 6720  
accatcgta accactacat cgagacaagc acggctcaact tccgtaccga gccgcaggaa 6780  
ccgcaggagt ggacggacga cctcgctcgt ctgcgggagc gctatccctg gctcgtcgcc 6840  
gaggtggacg gcgaggtcgc cggcatcgcc tacgcggggc cctggaaggc acgcaacgcc 6900  
tacgactgga cggccgagtc gaccgtgtac gtctccccc gccaccagcg gacgggactg 6960  
ggctccacgc tctacacca cctgctgaag tccctggagg cacagggtt caagagcgtg 7020  
gtcgtgtca tcgggctgcc caacgacccg agcgtgcgca tgcacgaggc gctcgatat 7080  
gccccccgcg gcatgctgcg ggccggccggc ttcaagcacg ggaactggca tgacgtgggt 7140  
ttctggcagc tggacttcag cctgccggta ccgccccgtc cggctcctgcc cgtcaccgag 7200  
atctgagatc acgcgttcta ggatccccg atgagctaag ctagctatat catcaattta 7260  
tgtattacac ataatatcgc actcagtctt tcatctacgg caatgtacca gctgatataa 7320  
tcagttattg aaatatttct gaatttaaac ttgcatcaat aaatttatgt ttttgccttg 7380  
actataatac ctgacttggt attttatcaa taaatattta aactatattt ctttcaagat 7440  
gggaattaac atctacaaat tgccttttct tatcgacat gtacgtatcg cg 7492

<210> 6

<211> 1695

<212> DNA

<213> Oryza sativa

<220>

<223> El promoter

<400> 6

ccgcagatcc ttcctgtgtga ttgttttatt aaaatttaaat atttatctgg aataacctacc 60  
aatatatagt agacttgtca agctgcaaga acttccaate gccgacaata ccaatagaga 120  
tccaaccacc ttaatatcat aaacaatctg attgttagtc cagaactata ttgagtagtg 180  
aacaacaata gcacattaac attatgagga ttattggcta actctgcaat tcaatattct 240  
gatgcgtcta atctgggtcaa ttttagcgct ccagaaagaa ttgcacaate ctgggacaat 300  
gttggcactg gaactgttgc atgtttttac atctcttatt aacgtagcaa aggagtagat 360  
tattatgtac caggagaaat ctcttcagat cctttccaca tgcaatgtcg taaagaacag 420  
atacagtgta cgtaggttg taatggacgg tcaatgccat ttccttgaag gcatgttcag 480  
agatgatgat ttcctgggac ctgggagggg ccttgaaatt cggaacagat tagttgagtt 540  
ttagtacctt atgtcttgcg ttatactacg tgaaatgcc a ttccttgaag ctgagtttct 600  
taccatctcc acaggaaata aagctaatac ctgtccaaga gtgggtgcggc atttgaccaa 660  
atgaagatca caagcatggc aagaatggca atctggcaaa ggagcggaat tatattgtat 720  
tctactacat cgaacaggaa ccataatcaat gtggccccag caaggacccc cgcagataag 780  
ttccgttct tccacagcag aatatccgca actgcatagc tccaacaat gaaatccaaa 840  
accacatcgg ctacagagaga agttatgata aaaggcacta attctgaata atttcctaga 900  
aagcgaataa taatagcaca ccttgacctc caccaagaag ctgttggtac gacttgtgcc 960  
catgaaatgg cattctgaca ttcctggcac tgcagaatc tctcggaata tgaggaggca 1020  
tagcttcgtg tgtgtatgtg tgtgggatat tacgtgcta aaactttgtg tttctgatcg 1080  
atctgggttag agagcatcgt ctttataagc acttaaaaaat ggtagtataa tctctcaagg 1140  
agcctatact gccaaaggaaa ggatagcttg gccctgtggg attagaccgt tgaagggaac 1200  
aaacgaatac agttacctta ccagatgttt gccacgacat gggcaacgtc attgctagac 1260  
caagaaggca agaagcaaag tttagctgtc aaaaaagata tgcctagaggc tttccagaat 1320  
atgttctatc tcagccagac caatgggggc aaaatttact actatttgcc atacattaac 1380  
cacgtaaaag tcttacactc aacctaacgt ttgaacggtc ctgttctggc caacggtgag 1440  
aatgcacctt atggacggga caacacttct ttaccgtgc tactgtctaca tctgttagac 1500  
ggtggacgcg tgaggtgctt tcgcatgac cgtccttggg tgttgcagtc acttgcgcac 1560  
gcttgcaccg tgactcacct gccacattgc ccccgccgtc gccggcgctt acaaaagcca 1620  
cacacgcacg ccggccacga taacccatcc tagcatcccg gtgtccagca agagatccat 1680  
caagccgtcg cgatg 1695

<210> 7

<211> 365

<212> DNA

<213> Artificial Sequence

<220>

<223> deleted E1 promoter

<400> 7

```
tcagccagac caatgggggc aaaatttact actatttgcc atacattaac cacgtaaaag   60
tcctacactc aacctaacig ttgaacggtc ctgttctggc caacggtgag aatgcaccta  120
atggacggga caacacttct ttaccgtgc tactgttaca tcctgtagac ggtggacgcg   180
tgaggtgctt tcgccaatgac cgtccitggt tgttgcagtc acttgcgcac gcttgcaccg  240
tgactcacct gccacattgc ccccgccgtc gccggcgccct acaaaagcca cacacgcacg   300
ccggccacga taacccatcc tagcatcccg gtgtccagca agagatccat caagccgtcg   360
cgatg                                           365
```

## CLAIMS


1. A method for producing a male-sterile plant comprising ligating a first promoter fragment to the upstream of an RNase gene, ligating a second promoter, which is the same as said first promoter or different therefrom, to the upstream of an RNase inhibitor protein gene, and transferring these genes into a plant genome to thereby make said plant substantially male-sterile.
2. The method for producing a male-sterile plant as claimed in claim 1 wherein said RNase gene is barnase gene.
3. A method for producing a male-sterile plant as claimed in claim 1 or 2 wherein said RNase inhibitor protein gene is Barstar gene.
4. A method for producing a male-sterile plant as claimed in any of claims 1 to 3 wherein the first promoter and the second promoter are both promoters causing anther-specific expression.
5. A method for producing a male-sterile plant as claimed in any of claims 1 to 4 wherein said first promoter is a part of the promoter represented by SEQ ID NO:6.
6. A method for producing a male-sterile plant as claimed in any of claims 1 to 5 wherein said first promoter is the promoter represented by SEQ ID NO:7.
7. A promoter comprising a part of the sequence represented by SEQ ID NO:6.
8. A promoter comprising the sequence represented by SEQ ID NO:7 or a sequence obtained by modifying the same by the substitution, deletion or addition of one or more

nucleotides.

9. A plasmid vector which has a T-DNA containing i) a first promoter fragment and an RNase gene the expression of which is induced by the first promoter, and ii) a second promoter being the same as the first promoter or different therefrom and an RNase inhibitor protein gene the expression of which is induced by the second promoter, said plasmid vector being capable of introducing said T-DNA into a plant cell genome when placed in agrobacterium-infected plant cells.

10. A transgenic plant cell which contains i) a first promoter fragment and an RNase gene the expression of which is induced by the first promoter, and ii) a second promoter being the same as the first promoter or different therefrom and an RNase inhibitor protein gene the expression of which is induced by this second promoter transferred into the genome thereof, and a male-sterile plant regenerated from said cell.

FIG. 1



# BIRCH, STEWART, KOLASCH & BIRCH, LLP

## COMBINED DECLARATION AND POWER OF ATTORNEY

ATTORNEY DOCKET NO.  
230-163P

### FOR PATENT AND DESIGN APPLICATIONS

PLEASE NOTE:  
YOU MUST  
COMPLETE THE  
FOLLOWING:

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Insert Title:

METHOD FOR PRODUCING MALE-STERILE PLANT

Fill in Appropriate  
Information -  
For Use Without  
Specification  
Attached:

the specification of which is attached hereto. If not attached hereto,

the specification was filed on \_\_\_\_\_ as  
United States Application Number \_\_\_\_\_; and /or

the specification was filed on September 12, 2000 as PCT  
International Application Number PCT/JP00/06222; and was  
amended under PCT Article 19 on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representatives or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns, except as follows.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Insert Priority  
Information:  
(if appropriate)

Prior Foreign Application(s)

279307/1999	Japan	09/30/1999
(Number)	(Country)	(Month/Day/Year Filed)
_____	(Country)	(Month/Day/Year Filed)
(Number)	(Country)	(Month/Day/Year Filed)
_____	(Country)	(Month/Day/Year Filed)
(Number)	(Country)	(Month/Day/Year Filed)
_____	(Country)	(Month/Day/Year Filed)

Priority Claimed

<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Yes	<input type="checkbox"/> No

Insert Provisional  
Application(s):  
(if any)

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

(Application Number)	(Filing Date)
_____	_____
(Application Number)	(Filing Date)
_____	_____

All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More Than 12 Months (6 Months for Designs) Prior To The Filing Date of This Application:

Insert Requested  
Information:  
(if appropriate)

Country	Application No.	Date of Filing (Month/Day/Year)
_____	_____	_____
_____	_____	_____

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Insert Prior U.S.  
Application(s):  
(if any)

(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)
_____	_____	_____
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)
_____	_____	_____



I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorneys identified below, unless the inventor(s) or assignee provides said attorneys with a written notice to the contrary:

16  
Terrell C. Birch (Reg. No. 19,382)  
Joseph A. Kolasch (Reg. No. 22,463)  
Bernard L. Sweeney (Reg. No. 24,448)  
Charles Gorenstein (Reg. No. 29,271)  
Leonard R. Svensson (Reg. No. 30,330)  
Andrew D. Meikle (Reg. No. 32,868)  
Joe McKinney Muncy (Reg. No. 32,334)  
C. Joseph Faraci (Reg. No. 32,350)

Raymond C. Stewart (Reg. No. 21,066)  
James M. Slattery (Reg. No. 28,380)  
Michael K. Mutter (Reg. No. 29,680)  
Gerald M. Murphy, Jr. (Reg. No. 28,977)  
Terry L. Clark (Reg. No. 32,644)  
Marc S. Weiner (Reg. No. 32,181)  
Andrew F. Reish (Reg. No. 33,443)  
Donald J. Daley (Reg. No. 34,313)

Send Correspondence to:

**BIRCH, STEWART, KOLASCH & BIRCH, LLP**

**P.O. Box 747 • Falls Church, Virginia 22040-0747**

**Telephone: (703) 205-8000 • Facsimile: (703) 205-8050**

PLEASE NOTE:  
YOU MUST  
COMPLETE THE  
FOLLOWING:

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of First or Sole  
Inventor:  
Insert Name of Inventor  
Insert Date This  
Document is Signed

Insert Residence  
Insert Citizenship

Insert Post Office  
Address

Full Name of Second  
Inventor, if any:

see above

Full Name of Third  
Inventor, if any

see above

Full Name of Fourth  
Inventor, if any

see above

Full Name of Fifth  
Inventor, if any

see above

GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Kazuyuki	HAMADA	Kazuyuki Hamada	May 18, 2001
Residence (City, State & Country)		CITIZENSHIP	
Shizuoka, Japan JPX		Japanese	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
c/o Orynova K.K. of 700, Higashibara, Toyoda-cho, Iwata-gun, Shizuoka 438-0802 Japan			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Fumio	NAKAKIDO	Fumio Nakakido	May 18, 2001
Residence (City, State & Country)		CITIZENSHIP	
Shizuoka, Japan JPX		Japanese	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
c/o Orynova K.K. of 700, Higashibara, Toyoda-cho, Iwata-gun, Shizuoka, 438-0802 Japan			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			
GIVEN NAME	FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP	
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)			